Histone Deacetylase Inhibitors in Cancer Therapy

Title:Histone Deacetylase Inhibitors in Cancer Therapy

Volume: 18 Issue: 28

Author(s): Yijie Sun, Yanyi Sun, Saichao Yue, Yaohe Wang and Fanghui Lu*

Affiliation:

• National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou,China

Keywords: Histone Deacetylase, Inhibitors, Epigenetics, Cancer treatment, RNA, DNA.

Abstract: Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. Here, we discuss HDAC inhibitors in terms of their functional mechanism establishing the anti-tumor effects and potential clinical applications including the synergistic effects in combinational treatment.

Cite this article as:

Sun Yijie, Sun Yanyi , Yue Saichao , Wang Yaohe and Lu Fanghui *, Histone Deacetylase Inhibitors in Cancer Therapy, Current Topics in Medicinal Chemistry 2018; 18 (28) . https://dx.doi.org/10.2174/1568026619666181210152115